What is the current situation in Poland, in terms of lung cancer screening?
In the National Cancer Strategy (NCS) 2020 – 2030, improving the effectiveness of secondary prevention of lung cancer is one of the thematic areas. The NCS commits to introducing new screening methods, particularly for the early detection of lung cancer, by the end of 2025.
What do you hope to achieve with SOLACE and what your message would be to other countries?
Above all, improving accessibility to early detection of lung cancer. Increasing the population’s awareness of the nature of screening and cancer risk factors.
An investment in prevention is an investment in the health of the whole population. There should be a sustained effort to develop early detection programmes that are effective and relevant to the health needs of the population.
What is your role and contribution to the project?
National Institute of Public Health NIH – National Research Institute is one of the partners involved in running the pilot study, in particular we aim to reach geographically excluded people. Within the study, we have a supporting and analytical role.
Why SOLACE is important to you?
SOLACE provides an opportunity to collaborate with partners in Europe, share experiences and develop best practices in the early detection of lung cancer.
This project is co-funded under the EU4Health Programme 2021–2027 under grant agreement no. 101101187. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.
